Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: quantman who wrote (2757)	6/6/2012 11:08:33 AM
From: Biomaven	Read Replies (1) \| Respond to of 3202

Same ballpark as Pfizer's drug in terms of efficacy as measured by ACR20/50/70. Substantially better performance on DAS28<2.6 (a standard measure of remission) with 37% and 22% for the 4mg and 8mg doses compared with around 10% for the Pfizer drug. Note this population had not failed biologics. My distant recollection is that the DAS28<2.6 rate for biologics in similar populations is in the mid-20% range, but I could easily be wrong on that. Anyone have a good number for this? Good looking results overall. Note this is once per day rather than the PFE's drugs BID. Peter